NDA 217766 · Long Grove Pharms
Vasopressin In Sodium Chloride 0.9%
Vasopressin · Intravenous
Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jul 11, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
331
81 Phase 3, 37 recruiting
FAERS reports
4,378
4,221 serious, 1,722 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 17, 2025.
Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )
Mechanism: Vasopressin causes vasoconstriction by binding to V 1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V 2 receptors which are coupled to adenyl cyclase.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 40UNITS/100ML (0.4UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription
- VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 50UNITS/50ML (1UNIT/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
- VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 20UNITS/100ML (0.2UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vasopressin" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Vasopressin for Septic Shock Pragmatic TrialPivotal-lookingCompleted
Intermountain Health Care, Inc.Academic, hospital or other
NCT06217562 · 3,959 participants · Start Feb 1, 2024 · Primary completion Feb 17, 2026
Drug: Vasopressin · For: Septic Shock
Sites: Burley, Idaho; American Fork, Utah; Cedar City, Utah · 13 sites in all
- EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With TolvaptanPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00071331 · 3,600 participants · Start Sep 2003 · Primary completion Jul 2006
Drug: Tolvaptan · For: Congestive Heart Failure
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 378 sites in all
- Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent SepsisPivotal-lookingRecruiting
Hospital do CoracaoAcademic, hospital or other
NCT06464510 · 2,800 participants (planned) · Start Nov 21, 2024 · Primary completion Aug 2027
Drug: Early Vasopressin; Norepinephrine and Vasopressin for Rescue · For: Septic Shock
Sites: Caxias do Sul, Brazil; Florianópolis, Brazil; São Paulo, Brazil · 8 sites in all
- Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac ArrestPivotal-lookingCompleted
Hospices Civils de LyonAcademic, hospital or other
NCT00127907 · 2,416 participants · Start May 2, 2004 · Primary completion Oct 1, 2007
Drug: epinephrine (1 mg/1 mL); arginine-vasopressin (40 UI/2 mL) · For: Cardiac Arrest
Sites: Pierre-Bénite, France
- The Effect of Prehospital Combination of Epinephrine, Vasopressin, and Steroid in OHCAPivotal-lookingRecruiting
National Taiwan University HospitalAcademic, hospital or other
NCT06203847 · 1,344 participants (planned) · Start Jul 16, 2024 · Primary completion Jul 31, 2026
Drug: Combination group; Standard group · For: Cardiac Arrest; Out-Of-Hospital Cardiac Arrest; Emergency Medical Services
Sites: Taipei, Taiwan
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) TrialPivotal-lookingRecruiting
Jason SperryAcademic, hospital or other
NCT05958342 · 1,050 participants (planned) · Start Jun 30, 2024 · Primary completion Mar 2027
Drug: Calcium Gluconate; Vasopressin and 1 more · For: Trauma; Hemorrhage
Sites: Chandler, Arizona; Tucson, Arizona; Little Rock, Arkansas · 18 sites in all
- Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal BleedingPivotal-lookingCompleted
Korea UniversityAcademic, hospital or other
NCT00966355 · 1,034 participants · Start Sep 2006 · Primary completion May 2010
Drug: Terlipressin; Somatostatin and 1 more · For: Variceal Bleeding, Cirrhosis
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,358
- off label use551
- hypotension509
- cardiogenic shock427
- multiple organ dysfunction syndrome423
- sepsis413
- condition aggravated401
- toxicity to various agents342
- acute kidney injury340
- stress319
- vomiting319
- abdominal pain301
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 17 |
| 2006 | 28 |
| 2007 | 32 |
| 2008 | 26 |
| 2009 | 43 |
| 2010 | 42 |
| 2011 | 134 |
| 2012 | 71 |
| 2013 | 36 |
| 2014 | 88 |
| 2015 | 67 |
| 2016 | 93 |
| 2017 | 144 |
| 2018 | 164 |
| 2019 | 169 |
| 2020 | 387 |
| 2021 | 615 |
| 2022 | 415 |
| 2023 | 535 |
| 2024 | 449 |
| 2025 | 512 |
| 2026 | 297 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vasopressin versus norepinephrine infusion in patients with septic shock.
Russell JA, Walley KR, Singer J, et al. · N Engl J Med 2008 · Comparative Study, Multicenter Study
- Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.
Gordon AC, Mason AJ, Thirunavukkarasu N, et al. · JAMA 2016 · Multicenter Study, Randomized Controlled Trial
- Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial.
Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. · Anesthesiology 2017 · Comparative Study, Randomized Controlled Trial
- THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.
Jia L, Wang P, Li C, et al. · Shock 2023 · Systematic Review, Network Meta-Analysis
- Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.
Nagendran M, Russell JA, Walley KR, et al. · Intensive Care Med 2019 · Meta-Analysis, Systematic Review
- Vasoactive Agents for the Management of Acute Variceal Bleeding: A Systematic Review and Meta-analysis.
Huaringa-Marcelo J, Huaman MR, Brañez-Condorena A, et al. · J Gastrointestin Liver Dis 2021 · Meta-Analysis, Systematic Review
Sponsor: Long Grove Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.